Louisiana State University and Agricultural & Mechanical College

Other

The Uab Research Foundation

Louisiana Tech University

Theravasc Inc.

Brd. of Sup. of Lsu and A&m College

Christopher Kevil

Anthony J Giordano

Kyle Chan

Amol Soin

John Glawe

Panayiotis P Constantinides

David J Lefer

Rakesh P Patel

Douglas R Flanagan

Robert McVie

Elvis A Peter

Xinggui Shen

Jonathan Steven Alexander

Rodney E Shackelford

Sibile Pardue

Clifton F Frilot

Leland Weiss

Paari Dominic

Gopi K Kolluru

Elizabeth Disbrow

Karen Y Stokes

Anthony Giordano

A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized HS in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.

Gasotransmitter metabolites and Alzheimer's disease

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

Pharmaceutical formulations of nitrite and uses thereof

A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (HS) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The HS donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The HS donor may be sugammadex. The HS donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Treatment for methamphetamine cardiovascular disease

The presently claimed invention is related to compositions and methods for treating HS related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the HS related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.

Methods and therapeutics to regulate hydrogen sulfide bioavailability

A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation

Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

Use of nitrite salts in chronic ischemia

CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.

CXCR4 and ROBO1 expression as markers for autoimmune diabetes

Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample. Methods and therapeutics for diagnosing and treating critical limb ischemia (CLI) versus non-critical limb ischemic peripheral artery disease (PAD) in a patient comprising determining a patient indicator value, where the patient indicator is value one of a total hydrogen sulfide metabolite plasma level, a total nitric oxide, nitrite, and nitrite (NOx) plasma level, a ratio of free hydrogen sulfide plasma level to total NOx plasma level, and a ratio of total hydrogen sulfide metabolite plasma level and total NOx plasma level, diagnosing the patient with as having CLI based on the patient indicator value, and administering to the patient a therapeutic for CLI.

Methods of diagnosis and treatment involving nitrite

A method of treating neuropathy in a subject, the method comprising identifying a subject who has neuropathy; and administering to the subject a pharmaceutical composition comprising one of inorganic nitrite and a pharmaceutically acceptable salt thereof.

Use of nitrite salts in treating tissue damage

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

A hydrogen sulfide (HS) detecting apparatus for measuring the concentrations of hydrogen sulfide species in a given sample is disclosed. The hydrogen sulfide detecting apparatus can comprise a plurality of reaction chambers separated from a plurality of trapping chambers by a (HS) permeable membrane, with the reaction chambers and trapping chambers each having buffer component(s) and/or reactive agents that expose the incoming sample to a particular pH and chemical environment in order to allow for the selective liberation and trapping of hydrogen sulfide from the sample.

Hydrogen sulfide detecting apparatus

Hydrogen sulfide (HS) levels in plasma are useful in diagnosing cardiovascular disease. The ratio of HS to NO in plasma is useful in diagnosing peripheral artery disease.

Growing community of inventors

Shreveport, LA, United States of America

Christopher Kevil